High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma

J Pharm Biomed Anal. 1995 Dec;14(1-2):165-74. doi: 10.1016/0731-7085(95)01616-3.

Abstract

A high-performance liquid chromatographic (HPLC) assay is described for the determination of the new antitumour drug N-benzoylstaurosporine (CGP 41 251; I) and four of its potential metabolites in micro-volumes (100 microliters) of plasma. After addition of an internal standard, the compounds were isolated from plasma by liquid-liquid extraction with diisopropyl ether. Chromatography was carried out using a 5 microns LiChrospher C-18 end-capped column (125 x 4.0 mm i.d.) and binary gradient elution with acetonitrile and a triethylamine-containing phosphate buffer (pH 3.6) as solvents. Fluorimetric detection was performed with excitation and emission wavelengths set at 286 and 386 nm, respectively. The absolute recovery was more than 98% for all of the investigated compounds. The limit of detection (LOD) for I and three metabolites was 0.1 ng ml-1 and the lower limit of quantitation (LLQ) was 0.2 ng ml-1 in 100 microliters of plasma. The LOD and LLQ for the fourth metabolite was 0.25 and 0.5 ng ml-1, respectively. The between-day and within-day precisions were always < 15% for all the analytes. A limited pharmacokinetic study in mice treated and with I demonstrated that the method is appropriate for this purpose.

MeSH terms

  • Animals
  • Antineoplastic Agents / blood*
  • Antineoplastic Agents / pharmacokinetics
  • Biotransformation
  • Calibration
  • Chromatography, High Pressure Liquid
  • Male
  • Mice
  • Mice, Inbred Strains
  • Quality Control
  • Rats
  • Reference Standards
  • Solutions
  • Staurosporine / analogs & derivatives*
  • Staurosporine / blood
  • Staurosporine / pharmacokinetics

Substances

  • Antineoplastic Agents
  • Solutions
  • Staurosporine
  • midostaurin